- Home
- LOCO vs MREO Comparison
LOCO vs MREO Comparison
Compare LOCO & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOCO | MREO |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 325.6M | 324.6M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | LOCO | MREO |
|---|---|---|
| Price | $10.56 | $0.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $14.50 | $3.90 |
| AVG Volume (30 Days) | 189.3K | ★ 39.0M |
| Earning Date | 03-05-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.62 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $480,815,000.00 | $500,000.00 |
| Revenue This Year | $5.44 | N/A |
| Revenue Next Year | $1.64 | $6,363.05 |
| P/E Ratio | $12.08 | ★ N/A |
| Revenue Growth | ★ 2.09 | N/A |
| 52 Week Low | $8.29 | $0.20 |
| 52 Week High | $12.65 | $3.26 |
Technical Indicators
Market Signals| Indicator | LOCO | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 42.96 | 31.42 |
| Support Level | $10.56 | $0.48 |
| Resistance Level | $11.24 | $0.78 |
| Average True Range (ATR) | 0.30 | 0.09 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 1.38 | 27.28 |
Price Performance
Historical ComparisonAbout LOCO El Pollo Loco Holdings Inc.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).